Toronto General Hospital, University Health Network
Toronto, Ontario, M5G 2C4, Canada
NCT Number: NCT05656404
Lung transplantation is a life-saving and life-prolonging therapy for patients with end-stage lung disease. However, the number of patients listed for lung transplantation exceeds the number of available donor lungs, leading to long wait times, deterioration in health and death of some listed patients. One way to address this issue is to reduce the number of donor lungs that are deemed unusable (declined) for transplantation. Often, donor lungs are declined for transplantation based on questionable function or inability to fully assess the organ in the donor. Due to this reason, up to 80% of potentially suitable lungs may be discarded. As a result, ex vivo lung perfusion (EVLP) was developed.
EVLP is a technique that enables the donor lungs to function in near physiological conditions outside the body, allowing surgeons to evaluate the suitability of the donor lungs for transplantation. Using this technique, centers have reported the recovery of around 70% of donor lungs that would have otherwise been deemed unusable and discarded.
The first generation Toronto EVLP technique started as a clinical trial in 2008 and became a part of the clinical standard of care at Toronto General Hospital in 2011. Since then, many clinical studies have shown that short- and long-term outcomes of recipients who received donor lungs assessed by the Toronto EVLP system were similar to those who received donor lungs deemed suitable to go straight to transplantation.
In partnership with Traferox Technologies Inc., surgeons and research team members developed the second generation TorEx Lung Perfusion System, which addresses engineering design limitations of the original Toronto EVLP system. It optimizes the Toronto EVLP technique by combining all the necessary equipment required to perform the procedure, while placing their controls within a central location. The technique of perfusion and ventilation as well as the perfusate solution remain the same between the two EVLP systems. Prior to this study, the TorEx Lung Perfusion System has not been used in clinical human lung transplantation.
The first purpose of this study is to look at the safety of using the TorEx Lung Perfusion System in 20 consented recipients. The second purpose to compare post-transplant outcomes between recipients who received donor lungs assessed by the TorEx Lung Perfusion System and a historical cohort of recipients who received donor lungs that were assessed by the first generation Toronto EVLP system.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Toronto, Ontario, M5G 2C4, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Recipient Inclusion Criteria
Recipient Exclusion Criteria
Donor Inclusion Criteria
Donor Exclusion Criteria
EVLP Transplant Suitability
When donor lungs with clinical indication for EVLP are allocated to consented recipients, the lungs will be assessed using the second generation TorEx Lung Perfusion System rather than the first generation Toronto EVLP technique (standard of care).
Time frame: 72 hours post-transplant
Time frame: 30 days, 1 year post-transplant
Time frame: Perioperative
Time frame: Perioperative
Time frame: 1 year post-transplant
Time frame: 1 year post-transplant
Time frame: 1 year post-transplant
University Health Network, Toronto
Other
Evaluation of the TorEx Lung Perfusion System in Clinical Lung Transplantation: A Safety Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06089434
Deglutition Disorders, Digestive System Diseases
Los Angeles, California, United States
View Trial DetailsNCT05041426
CMV, Lung Transplant
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT04601818
Lung Transplant, To Compare Lung Transplant Outcomes Between Study Patients and Standard Patients Who Have Already Undergone Lung Transplantation by Conventional Procedures
Gainesville, Florida, United States
View Trial DetailsNCT06268171
Atrophy, Lung Transplant
Suresnes, Hauts de seine, France
View Trial Details